




First-in-class drug lead candidate (A229) for treating ocular diseases

PPAR α agonist, A229, exhibits strong potency and demonstrates efficacy in *in-vitro* models of diabetic retinopathy.



IP Status: Provisional Patent Application Filed

Applications

- Ocular disease treatment
- Research tool

Key Benefits & Differentiators

- **Subtype selectivity:** A229 shows subtype selectivity for PPAR α over other isoforms, minimizing potential off-target effects.
- **Enhanced potency:** A229 exhibits potent activity, potentially reducing the required dosage and side effects while maintaining therapeutic efficacy.
- **Efficacy in retinal cells:** In hRPE cells under conditions that model DR, A229 upregulates PPAR α target genes, improves cell viability, reduces VEGF production, and protects against ROS production.

Technology Overview

Age-related macular degeneration (AMD) and diabetic retinopathy (DR) stand as leading causes of blindness and low vision in the United States. The conventional treatment for these conditions involves direct intraocular injection of anti-VEGF antibodies. However, this treatment method presents challenges, including the need for recurrent injections and a significant percentage (40%) of patients not responding adequately to therapy. Consequently, there is a pressing need for novel therapies that surpass or complement current approaches. Such innovations would greatly benefit patients, particularly those who remain refractory to anti-VEGF treatment options.

Technology ID

2023-194

Category

Life Sciences/Biochemicals & Small Molecules

Life Sciences/Human Health

Life Sciences/Pharmaceuticals

Life Sciences/Research Tools

Life Sciences/Therapeutics

Learn more



Researchers from the University of Minnesota have developed a first-in-class drug lead candidate, A229, for potential treatment of ocular diseases. A229 targets Peroxisome proliferator-activated receptor α (PPAR α), a ligand-activated transcription factor that is involved in lipid metabolism of various tissues. Previous studies have shown that PPAR α agonism significantly reduces the progression of DR, but currently available drugs that target PPAR α suffer from low affinity and lack selectivity among PPAR subtypes. A229 exhibits good potency and subtype selectivity for PPAR α when assessed in a commercial primary luciferase-based cell assay. In human retinal pigment epithelial (hRPE) cells under conditions that model DR, A229 upregulates PPAR α target genes, improves cell viability, reduces VEGF production, and protects against ROS production, aligning with PPAR α agonism expectations in a disease-relevant context. Based on this data, A229 is a promising drug candidate for further advanced in-vitro and in-vivo model characterization, with potential for commercial development as a treatment for ocular diseases.

Phase of Development

TRL: 3-4

In-vitro data has been generated for A229. In vivo studies are underway.

Desired Partnerships

This technology is now available for:

- License
- Sponsored research
- Co-development

Please contact our office to share your business' needs and learn more.

Researchers

- [Adam Duerfeldt, PhD](#) Associate Professor, Department of Medicinal Chemistry

References

1. Julia J. Lee, Ziwei Hu, Yuhong Anna Wang, Dinesh Nath, Wentao Liang, Yi Cui, Jian-Xing Ma, and Adam S. Duerfeldt(2023) , <https://doi.org/10.1021/acsmchemlett.3c00056>, <https://pubs.acs.org/doi/10.1021/acsmchemlett.3c00056?ref=pdf>, 14, 6, 766–776